ICMH
JSPRW

Integrity Capital Management (HK)’s Japer Therapeutics Warrants JSPRW Stock Holding History

Integrity Capital Management (HK)’s Portfolio JSPRW Stock Details JSPRW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-5,439
Closed -$2K – 13
2022
Q1 		$2K Sell
5,439
-44,561
-89% -$24.8K 0.01% 163
2021
Q4 		$74K Buy
+50,000
New +$69.7K 0.23% 82

Other funds holding JSPRW

HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.21B AUM 169.99% 1-Year Est. Return
ICM
Ionic Capital Management New York $690M AUM 70.34% 1-Year Est. Return
TCM
Tenor Capital Management New York $7.09B AUM 3.55% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.1B AUM 64.05% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
ZA
Zazove Associates Incline Village, Nevada $1.22B AUM 1.92% 1-Year Est. Return
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Integrity Capital Management (HK)'s JSPRW Position: Q2 2022 in Review

Integrity Capital Management (HK) sold out of Japer Therapeutics Warrants (JSPRW) in Q2 2022, closing a stake of 5,439 shares — an estimated $2K sold.

Integrity Capital Management (HK) first reported a position in JSPRW in Q4 2021 and held it in 2 quarters. The position peaked at $74K in Q4 2021. 14 funds tracked by Wall St. Rank hold JSPRW as of Q2 2022.

  • Integrity Capital Management (HK) reported no remaining Japer Therapeutics Warrants position as of Q2 2022 after selling out during the quarter.
  • Integrity Capital Management (HK) sold 5,439 Japer Therapeutics Warrants shares in Q2 2022, an estimated $2K.
  • Integrity Capital Management (HK) first reported a position in Japer Therapeutics Warrants in Q4 2021 and held it in 2 quarters.
  • Integrity Capital Management (HK)'s Japer Therapeutics Warrants position peaked at $74K in Q4 2021.
  • 14 funds tracked by Wall St. Rank held Japer Therapeutics Warrants as of Q2 2022.

Based on Integrity Capital Management (HK)'s 13F filing for Q2 2022.